CAJ | 학술논문

目的观察同期放化疗治疗鼻腔NK/T细胞淋巴瘤的初步临床效果并分析预后因素.方法选择31例Ⅱ期鼻腔NK/T细胞淋巴瘤初治患者,均接受根治性调强放疗(IMRT)+门冬酰胺酶方案化疗和辅助化疗.结果 31例患者主要不良反应为1～2级的口腔炎、骨髓抑制和口干.放疗后3个月完全缓解率达83.9％(26/31),2年总生存率为77％.单因素分析和多因素分析均显示国际预后指数(IPI)、近期疗效是独立预后因素(P＜0.05).结论 Ⅱ期鼻腔NK/T细胞淋巴瘤患者行同期放化疗易于耐受,可获得较高的近期局部完全缓解率和总生存率,IPI及近期疗效是主要的预后因素.
목적 관찰동기방화료치료비강NK/T세포림파류적초보림상효과병분석예후인소.방법 선택31례Ⅱ기비강NK/T세포림파류초치환자,균접수근치성조강방료(IMRT)+문동선알매방안화료화보조화료.결과 31례환자주요불량반응위1～2급적구강염、골수억제화구간.방료후3개월완전완해솔체83.9％(26/31),2년총생존솔위77％.단인소분석화다인소분석균현시국제예후지수(IPI)、근기료효시독립예후인소(P＜0.05).결론 Ⅱ기비강NK/T세포림파류환자행동기방화료역우내수,가획득교고적근기국부완전완해솔화총생존솔,IPI급근기료효시주요적예후인소.
Objective To observe the primary clinical effect of concurrent radiochemotherapy for patients with nasal cavity natural killer (NK)/T cell lymphoma and to analyze the prognostic factors.Methods 31 primary untreated patients with stage Ⅱ nasal cavity NK/T cell lymphoma were enrolled for this study.All patients underwent concurrent radiochemotherapy with intensity-modulated radiotherapy technique + asparaginase based chemotherapeutic agents and adjuvant chemotherapy.Results The main toxicities were mouth mucocitis,myelosuppression and xerosmia at grade 1 or 2.31 patients achieved good clinical shortterm effect with high local complete remission rate at the 3rd month after radiotherapy [83.9 ％ (26/31)],and the 2-year overall survival rate was 77 ％.Univariate and multivariate analysis suggested IPI score and clinical short-term effect were the significant independent survival prognostic factors (P ＜ 0.05).Conclusions Concurrent radiochemotherapy for stage Ⅱ nasal cavity NK/T cell lymphoma can be well tolerated by patients with mild toxicities,and can improve both clinical short-term effect and overall survival by high local complete remission rate.IPI score and clinical short-term effect are the important survival prognostic factors.